{"id":"NCT03751124","sponsor":"Myovant Sciences GmbH","briefTitle":"Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","officialTitle":"An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-16","primaryCompletion":"2021-02-19","completion":"2021-10-20","firstPosted":"2018-11-23","resultsPosted":"2024-06-25","lastUpdate":"2024-06-25"},"enrollment":229,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Uterine Leiomyoma","Uterine Fibroids"],"interventions":[{"type":"DRUG","name":"Relugolix","otherNames":["TAK-385"]},{"type":"DRUG","name":"Estradiol/norethindrone acetate","otherNames":["E2/NETA","Low-dose hormonal add-back"]},{"type":"DRUG","name":"Placebo for relugolix","otherNames":[]},{"type":"DRUG","name":"Placebo for E2/NETA","otherNames":[]}],"arms":[{"label":"Relugolix plus E2/NETA","type":"EXPERIMENTAL"},{"label":"Placebo tablets and capsules","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this randomized withdrawal study are to evaluate the long-term efficacy and safety of the combination of relugolix, estradiol (E2) and norethindrone acetate (NETA), once daily, for up to 104 weeks in patients with uterine fibroids who have completed a total of 52 weeks of treatment, including a 24-week treatment period in a parent study (study MVT-601-3001 or MVT-601-3002) and a 28-week treatment period in the open-label extension study (MVT-601-3003), and who meet the definition of responder, defined as a patient who demonstrates a menstrual blood loss of \\< 80 mL and at least a 50% reduction from parent study baseline menstrual blood loss volume on the alkaline hematin analysis of the feminine products returned at Week 48 in the extension study.","primaryOutcome":{"measure":"Percentage Of Participants Who Maintained MBL Volume Of <80 Milliliters (mL) At Week 76 During The Randomized Treatment Period","timeFrame":"Week 52/Baseline up to Week 76","effectByArm":[{"arm":"Relugolix Plus E2/NETA (Group A)","deltaMin":78.43,"sd":null},{"arm":"Placebo (Group B)","deltaMin":15.08,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":104,"countries":["United States","Brazil","Chile","Czechia","Hungary","Italy","Poland","South Africa"]},"refs":{"pmids":["37666383"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":116},"commonTop":["Nasopharyngitis","Headache","Dysmenorrhoea","Hot flush","Hypertension"]}}